These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 27880943)

  • 21. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
    Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
    PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer.
    Rokudai S
    Methods Mol Biol; 2020; 2108():297-303. PubMed ID: 31939190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant TP53 disrupts age-related accumulation patterns of somatic mutations in multiple cancer types.
    Zhang W; Flemington EK; Zhang K
    Cancer Genet; 2016 Sep; 209(9):376-380. PubMed ID: 27751354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of critical pathways and hub genes in
    Sun J; Zhang K; Cai Z; Li K; Zhao C; Fan C; Wang J
    Biomark Med; 2019 Jul; 13(10):831-840. PubMed ID: 31116024
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations.
    Park S; Lee J; Kim YH; Park J; Shin JW; Nam S
    Sci Rep; 2016 Oct; 6():34822. PubMed ID: 27708434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.
    Khan R; Pari B; Puszynski K
    Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association mining of mutated cancer genes in different clinical stages across 11 cancer types.
    Hu W; Li X; Wang T; Zheng S
    Oncotarget; 2016 Oct; 7(42):68270-68277. PubMed ID: 27556693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression signatures of TP53 mutations in serous ovarian cancers.
    Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
    BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Shirole NH; Pal D; Kastenhuber ER; Senturk S; Boroda J; Pisterzi P; Miller M; Munoz G; Anderluh M; Ladanyi M; Lowe SW; Sordella R
    Elife; 2016 Oct; 5():. PubMed ID: 27759562
    [No Abstract]   [Full Text] [Related]  

  • 33. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of protein interactome networks prioritizes candidate genes with cancer signatures.
    Li Y; Sahni N; Yi S
    Oncotarget; 2016 Nov; 7(48):78841-78849. PubMed ID: 27791983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
    Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
    Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
    Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
    Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.